Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.
Coelho T, Marques W Jr, Dasgupta NR, Chao CC, Parman Y, França MC Jr, Guo YC, Wixner J, Ro LS, Calandra CR, Kowacs PA, Berk JL, Obici L, Barroso FA, Weiler M, Conceição I, Jung SW, Buchele G, Brambatti M, Chen J, Hughes SG, Schneider E, Viney NJ, Masri A, Gertz MR, Ando Y, Gillmore JD, Khella S, Dyck PJB, Waddington Cruz M; NEURO-TTRansform Investigators.
JAMA. 2023 Oct 17;330(15):1448-1458. doi: 10.1001/jama.2023.18688.
Vascular Cognitive Impairment and Dementia.
Chang Wong E, Chang Chui H.
Continuum (Minneap Minn). 2022 Jun 1;28(3):750-780. doi: 10.1212/CON.0000000000001124.
Hereditary transthyretin amyloidosis (ATTRv).
Triposkiadis F, Briasoulis A, Starling RC, Magouliotis DE, Kourek C, Zakynthinos GE, Iliodromitis EK, Paraskevaidis I, Xanthopoulos A.
Curr Probl Cardiol. 2025 Apr;50(4):103019. doi: 10.1016/j.cpcardiol.2025.103019. Epub 2025 Feb 13.
Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review.
Delgado D, Dabbous F, Shivappa N, Mazhar F, Wittbrodt E, Shridharmurthy D, Järbrink K.
Orphanet J Rare Dis. 2025 Jan 16;20(1):29. doi: 10.1186/s13023-025-03547-0.
A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Gentile L, Coelho T, Dispenzieri A, Conceição I, Waddington-Cruz M, Kristen A, Wixner J, Diemberger I, Gonzalez-Moreno J, Cariou E, Maurer MS, Planté-Bordeneuve V, Garcia-Pavia P, Tournev I, Gonzalez-Costello J, Duarte AG, Grogan M, Mazzeo A, Chapman D, Gupta P, Glass O, Amass L; THAOS investigators.
Orphanet J Rare Dis. 2023 Nov 10;18(1):350. doi: 10.1186/s13023-023-02962-5.
Diagnosis and Management of Mixed Phenotype Hereditary Transthyretin Amyloidosis: A Case-Based, Canadian Perspective.
Fine N, Ducharme A, Matte G, Mezei M, Bril V, Delgado D.
CJC Open. 2025 Mar 10;7(5):614-627. doi: 10.1016/j.cjco.2025.03.002. eCollection 2025 May.
ATTR Epidemiology, Genetics, and Prognostic Factors.
Obi CA, Mostertz WC, Griffin JM, Judge DP.
Methodist Debakey Cardiovasc J. 2022 Mar 14;18(2):17-26. doi: 10.14797/mdcvj.1066. eCollection 2022.
Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey.
González-Moreno J, Dispenzieri A, Grogan M, Coelho T, Tournev I, Waddington-Cruz M, Wixner J, Diemberger I, Garcia-Pavia P, Chapman D, Gupta P, Glass O, Amass L; THAOS investigators.
Cardiol Ther. 2024 Mar;13(1):117-135. doi: 10.1007/s40119-023-00344-3. Epub 2023 Dec 20.
Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy.
Poli L, Labella B, Cotti Piccinelli S, Caria F, Risi B, Damioli S, Padovani A, Filosto M.
Front Neurol. 2023 Oct 5;14:1242815. doi: 10.3389/fneur.2023.1242815. eCollection 2023.
Transthyretin cardiac amyloidosis.
Tomoaia R, Beyer R, Manole S, Chirilă A, Dădârlat-Pop A, Minciună IA, Pop D.
Med Pharm Rep. 2021 Aug;94(Suppl No 1):S11-S14. doi: 10.15386/mpr-2219. Epub 2021 Aug 10.
